Evidence map›Paper›PMID 41677839›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2026

TFR2 p.A75V mutation aggravates liver iron overload in alcoholic liver disease via ERK pathway.

Chao Xie, Yingying Liu, Xiaofan Wang, Long Huang, Xiaoming Wang, Wei Zhang, Lina Wu, Tianhui Liu, Ping Wang, Lin Liu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chao Xie *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Yingying Liu *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Xiaofan Wang *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Long Huang *Liver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Xiaoming WangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Wei ZhangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Lina WuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Tianhui LiuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Ping WangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Lin LiuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Xu FanLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Jidong JiaLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China.
Xiaojuan OuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China. ouxj16@126.com.
Anjian XuExperimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Xicheng District, Beijing, 100050, China. xuanjian1981@sina.com.
Min CongLiver Research Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong-an Road, Xicheng District, Beijing, China. maomao0623@sina.com.ORCID http://orcid.org/0000-0003-0188-3661

Funding

National Natural Science Foundation of China 82170614National Natural Science Foundation of China 82370898
6 · The paper itself

Abstract

Liver iron overload, a contributing factor to liver damage, is frequently observed in advanced alcoholic liver disease (ALD). Genetic factors may influence the progression of ALD. This study explored the involvement of hemochromatosis-related genes in liver iron deposition among ALD patients. Clinical data from 97 ALD patients revealed that those with liver iron overload had worse liver function and prognosis. Among 43 patients who underwent exon sequencing of the HFE, HJV, HAMP, TFR2, and SLC40A1 genes, the TFR2 p.A75V mutation emerged as a potential contributor to iron overload. To further investigate, we developed a novel mouse model of ALD with liver iron overload. Administration of recombinant AAV carrying the wild-type TFR2 gene significantly reduced iron deposition in hepatocytes, whereas the TFR2 p.A75V mutation did not alleviate hepatic iron overload. This mutation impairs HAMP induction by disrupting the ERK pathway, likely due to abnormal cytoplasmic localization of the TFR2 protein. In conclusion, the TFR2 p.A75V mutation in ALD may decrease hepatocyte sensitivity to iron stimulation by inhibiting HAMP expression via the ERK pathway, thereby exacerbating iron overload both in vivo and in vitro. KEY MESSAGES: The study identifies the TFR2 p.A75V mutation as a key genetic factor worsening liver iron overload in ALD patients, linked to poorer liver function and prognosis. A novel ALD mouse model with iron overload demonstrates that the TFR2 p.A75V mutation impairs iron regulation. TFR2 p.A75V mutant disturbs the ERK pathway in HAMP induction and causes abnormal cytoplasmic localization of the TFR2 Protein.

Indexed as

Iron OverloadLiverLiver Diseases, AlcoholicMAP Kinase Signaling SystemMutationReceptors, TransferrinAnimalsDisease Models, AnimalFemaleHepatocytesHepcidinsHumansIronMaleMiceMiddle AgedHAMP protein, humanHepcidinsIronReceptors, TransferrinTFR2 protein, humanAlcoholic liver diseaseHepcidinIron overloadTransferrin receptor 2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.